Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
公司代碼CAI
公司名稱Caris Life Sciences Inc
上市日期Jun 18, 2025
成立日期2020
CEOMr. David Dean Halbert
員工數量- -
證券類型Ordinary Share
年結日Jun 18
公司地址750 West John Carpenter Freeway
城市IRVING
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編75039
電話18667718946
網址https://www.carislifesciences.com/
公司代碼CAI
上市日期Jun 18, 2025
成立日期2020